Legal counsel representing a physician petitioning for the rescheduling of psilocybin has formally requested that the Drug Enforcement Administration (DEA) accelerate its review process. The petition, which centers on granting terminal patients access to psilocybin-assisted therapy, has faced persistent procedural delays. The petitioner’s attorney argues that the DEA is now under increased pressure to act following a directive from the Trump administration aimed at streamlining federal access to psychedelic medicines.
This legal push highlights a widening gap between administrative inertia at the DEA and the executive branch’s stated intent to foster medical research and clinical access to psychedelics. For stakeholders in the cannabis sector, this development serves as a proxy for broader regulatory shifts. While the DEA remains a primary bottleneck for both cannabis and psychedelic reform, the administration’s focus on the medical utility of controlled substances suggests a pivot toward a more research-friendly federal stance.
The attorney’s letter serves as both a reminder of existing administrative law requirements and a tactical move to leverage new executive policy to compel agency action. If the DEA does move forward with rescheduling or streamlining access for psilocybin, it could set a critical administrative precedent for the future classification of cannabis and other plant-based therapeutic compounds. The resolution of this petition remains uncertain, but it underscores the ongoing friction between federal scheduling mandates and the expanding movement for therapeutic deregulation.